$3.33
4.06% yesterday
NYSE, Nov 25, 10:00 pm CET
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Prime Medicine Stock price

$3.33
-0.70 17.37% 1M
-3.60 51.91% 6M
-5.53 62.42% YTD
-3.70 52.63% 1Y
-13.67 80.41% 3Y
-13.67 80.41% 5Y
-13.67 80.41% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.13 4.06%
ISIN
US74168J1016
Symbol
PRME
Sector
Industry

Key metrics

Market capitalization $399.70m
Enterprise Value $265.42m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 331.78
P/S ratio (TTM) P/S ratio 499.63
P/B ratio (TTM) P/B ratio 2.30
Revenue (TTM) Revenue $800.00k
EBIT (operating result TTM) EBIT $-212.79m
Free Cash Flow (TTM) Free Cash Flow $-190.32m
Cash position $175.53m
EPS (TTM) EPS $-2.01
P/E forward negative
P/S forward 40.34
EV/Sales forward 26.79
Short interest 27.65%
Show more

Is Prime Medicine a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Prime Medicine Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Prime Medicine forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Prime Medicine forecast:

Buy
83%
Hold
17%

Financial data from Prime Medicine

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.80 0.80
-
100%
- Direct Costs 5.66 5.66
66% 66%
708%
-4.86 -4.86
71% 71%
-608%
- Selling and Administrative Expenses 40 40
474% 474%
4,954%
- Research and Development Expense 163 163
20% 20%
20,330%
-207 -207
30% 30%
-25,891%
- Depreciation and Amortization 5.66 5.66
66% 66%
708%
EBIT (Operating Income) EBIT -213 -213
21% 21%
-26,599%
Net Profit -219 -219
28% 28%
-27,406%

In millions USD.

Don't miss a Thing! We will send you all news about Prime Medicine directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prime Medicine Stock News

Positive
Seeking Alpha
about 3 hours ago
Prime Medicine's proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME's pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson's Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 mil...
Neutral
GlobeNewsWire
5 days ago
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Wilson Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Wilson Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeuti...
Neutral
GlobeNewsWire
20 days ago
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences:
More Prime Medicine News

Company Profile

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

Head office United States
CEO Keith Gottesdiener
Employees 234
Founded 2019
Website www.primemedicine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today